House BillHR 685Health personnelDrug safety, medical device, and laboratory regulation
SAVE Moms and Babies Act of 2025
INTRO JAN 23· LAST ACTION JAN 23
READING
6MIN
COSPONSORS
78
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8
Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-written
This bill matters because it would dramatically change how medication abortion, a common method of ending a pregnancy, is regulated and accessed in the United States. If passed, it would essentially stop the introduction of new drugs for this purpose and impose significant restrictions on existing ones, potentially making them much harder for patients to obtain, especially in rural areas or for those who prefer more private access. It moves away from the FDA's current approach, which has, in some cases, allowed for broader access, including through telemedicine and pharmacies.
For voters, this bill represents a significant shift in federal policy regarding reproductive healthcare. If it becomes law, it would restrict options for women seeking to end a pregnancy and place new burdens on healthcare providers. If it doesn't pass, the current federal regulations for medication abortion would remain in place, allowing for continued access as determined by current FDA rules and state laws.
KEY PROVISIONS
5AI-extracted
PROVISION 01
Prohibits the FDA from approving any new abortion drugs for marketing or granting exemptions for their investigational (research) use.
This stops the future development and introduction of any new medications intended to end a pregnancy.
PROVISION 02
For previously approved abortion drugs, it prohibits their use after 70 days of pregnancy and requires them to be dispensed only in-person by the prescribing healthcare practitioner in a clinic, medical office, or hospital.
This significantly restricts the timeframe for using medication abortion and eliminates pharmacy or mail-order access.
PROVISION 03
Requires healthcare practitioners who prescribe abortion drugs to be certified, demonstrating specific medical capabilities, such as accurately assessing pregnancy duration, diagnosing ectopic pregnancies, and providing surgical intervention for complications.
This imposes new professional requirements on providers and aims to ensure they are equipped to handle potential complications.
PROVISION 04
Mandates increased reporting of all known adverse events (like deaths or hospitalizations) associated with abortion drugs by prescribers, manufacturers, and other healthcare practitioners to the FDA.
This aims to collect more comprehensive safety data on the use of these medications.
PROVISION 05
Rescinds (cancels) any investigational use exemptions for abortion drugs that were granted before this bill's enactment, three years after the bill becomes law, if they would be prohibited under the new rules.
This would halt ongoing research studies on abortion drugs that do not meet the new, stricter criteria.
This bill matters because it would dramatically change how medication abortion, a common method of ending a pregnancy, is regulated and accessed in the United States. If passed, it would essentially stop the introduction of new drugs for this purpose and impose significant restrictions on existing ones, potentially making them much harder for patients to obtain, especially in rural areas or for those who prefer more private access. It moves away from the FDA's current approach, which has, in some cases, allowed for broader access, including through telemedicine and pharmacies.
For voters, this bill represents a significant shift in federal policy regarding reproductive healthcare. If it becomes law, it would restrict options for women seeking to end a pregnancy and place new burdens on healthcare providers. If it doesn't pass, the current federal regulations for medication abortion would remain in place, allowing for continued access as determined by current FDA rules and state laws.
KEY PROVISIONS
AI-extracted
high
Prohibits the FDA from approving any new abortion drugs for marketing or granting exemptions for their investigational (research) use.
This stops the future development and introduction of any new medications intended to end a pregnancy.
high
For previously approved abortion drugs, it prohibits their use after 70 days of pregnancy and requires them to be dispensed only in-person by the prescribing healthcare practitioner in a clinic, medical office, or hospital.
This significantly restricts the timeframe for using medication abortion and eliminates pharmacy or mail-order access.
med
Requires healthcare practitioners who prescribe abortion drugs to be certified, demonstrating specific medical capabilities, such as accurately assessing pregnancy duration, diagnosing ectopic pregnancies, and providing surgical intervention for complications.
This imposes new professional requirements on providers and aims to ensure they are equipped to handle potential complications.
med
Mandates increased reporting of all known adverse events (like deaths or hospitalizations) associated with abortion drugs by prescribers, manufacturers, and other healthcare practitioners to the FDA.
This aims to collect more comprehensive safety data on the use of these medications.
low
Rescinds (cancels) any investigational use exemptions for abortion drugs that were granted before this bill's enactment, three years after the bill becomes law, if they would be prohibited under the new rules.
This would halt ongoing research studies on abortion drugs that do not meet the new, stricter criteria.
Ongoing investigational use exemptions for abortion drugs are deemed rescinded (canceled) if they would be prohibited under the new rules.
GLOSSARY
AI-written
Federal Food, Drug, and Cosmetic Act
The main law governing how food, drugs, medical devices, and cosmetics are made and sold in the U.S., overseen by the FDA.
Abortion Drug
Any medication intended to end a pregnancy by intentionally killing an unborn child or terminating the pregnancy, excluding cases like ectopic pregnancy treatment or removing a dead unborn child.
Investigational Use Exemption
A special permission from the FDA that allows a drug to be used in clinical trials (research) before it has been fully approved for sale to the public.
Gestation
The length of a pregnancy, counted from the first day of the last menstrual period.
Risk Evaluation and Mitigation Strategy (REMS)
A program required by the FDA for certain drugs with serious safety concerns to ensure that the benefits of the drug outweigh its risks, often involving specific requirements for prescribers and patients.
Ectopic Pregnancy
A pregnancy in which the fertilized egg implants outside the uterus, usually in a fallopian tube, which is not viable and can be life-threatening to the woman.
Adverse Event
ACTION TIMELINE
2 EVENTS
JAN 23, 25
Introduced in House
INTROREFERRAL
JAN 23, 25
Referred to the House Committee on Energy and Commerce.
A harmful or undesired outcome experienced by a patient, such as a serious injury, hospitalization, or death, that may or may not be related to a drug or medical treatment.
Unborn child
An individual human organism, beginning at fertilization, until the point of being born alive.
